New med. MS and herpes
Dont know if this is of interestResearchers at the University of Alabama at Birmingham have reported that a set of novel methylenecyclopropane (MCP) nucleoside analogs, synthesized by Microbiotix, Inc., have shown increased activity against a broad spectrum of human herpesviruses. The new agents are derivations of the compound cyclopropavir (CPV), currently in human phase I clinical studies, which has previously been shown to exhibit good antiviral activity against human beta-and gamma-herpes viruses, including HCMV, EBV, HHV-6A, HHV-6B, and HHV-8. In addition, all but one of the new analogs had potent anti-viral activity against HHV-6B that was greater than that of cidofovir (CDV). Furthermore, some of the new analogs have demonstrated an even broader spectrum of anti-herpes activity, with significant inhibition of the alpha-herpes viruses HSV-1, HSV-2, and VZV as well.
A new group of antiherpetics (antivirals against herpesviruses) that addresses the entire class (rather than only alphas or betas or gammas) could be a huge boon for ME/CFS patients. The fact that it's already in Phase 1 trials gives hope for a new treatment sooner than 10-15 years out.
Dr. Jussi Oskari Virtanen, who works in Steve Jacobson’s laboratory at the NINDS, has published findings that further strengthen the relationship between HHV-6, EBV, and multiple sclerosis. The report demonstrates that 24% of 37 CSF samples from MS patients had HHV-6 reactive oligoclonal bands (OCBs) and 14% had EBV OCBs, compared to none in patients with other inflammatory neurological diseases (p=0.005). In addition, brain imaging analysis also showed that MS patients with viral DNA detected in the CSF exhibited more brain contrast enhancing lesions (CELs) than those who were virus-negative.